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. Cholangiocarcinoma is the second most common hepatic malignancy after hepatocellular carcinoma (HCC), and the overall incidence of cholangiocarcinoma has increased pro gressively worldwide over the past four decades [2] [3] [4] . Intrahepatic cholangiocarcinomas (iCCAs) arise above the secondorder bile ducts, whereas the cystic duct is the anatomical point of distinction between perihilar chol angiocarcinomas (pCCAs) and distal cholangio carcinomas (dCCAs) 1 . Two histo pathological subtypes of the disease are predominant: cancers with cylindrical, mucinproducing glands; and those with cuboidal, nonmucinproducing glands 5 . However, cholangiocarcinomas commonly have a mixture of these histopathological characteristics. Importantly, substantial differences exist in the molec ular characteristics, biology, and management of the anatomical cholangiocarcinoma subtypes 1 .
Cholangiocarcinomas are aggressive tumours, and most patients have advancedstage disease at presen tation 6 . Diagnosing cholangiocarcinoma at an early stage remains a challenge owing to its 'silent' clinical character (most patients with early stage disease are asymptomatic), difficult to access anatomical location, and highly desmoplastic, paucicellular nature, which limits the sensitivity of cytological and pathological diag nostic approaches. Nonetheless, advanced cyto logical techniques, such as fluorescence in situ hybridi zation (FISH) and mutational analysis, have emerged as essential diagnostic modalities 7, 8 . Surgery is the preferred treatment option for all three disease subtypes, but a minority of patients (approxi mately 35%) have early stage disease that is amenable to surgical resection with curative intent 6 . Similarly, only a small subset of carefully selected patients with pCCA are candidates for liver transplantation following neo adjuvant chemoradiation 9 . Typically, iCCA is consid ered a formal contraindication for liver transplantation;
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however, results published in 2016 support liver trans plantation as a treatment option for patients with 'very early' iCCA 10 . For patients with advancedstage or un resectable cholangiocarcinoma, the available systemic therapies are of limited effectiveness: the median overall survival with the current standardofcare chemo therapy regimen (gemcitabine and cisplatin) is <1 year 11 . The desmoplastic stroma and genetic heterogeneity both contribute to the resistance of cholangiocarcinoma to therapy; the rich tumour microenvironment fosters potent survival signals and might pose a barrier to the delivery of chemotherapy to the tumour. Advances in genetic profiling and classifications coupled with tar geted therapies, radiation therapy, and immunotherapy might help improve survival outcomes of patients with this otherwise devastating malignancy. Herein, we review these advances, focusing on the current stateoftheart and emerging concepts.
Evolving epidemiology
The anatomical subtypes of cholangiocarcinoma differ geographically in their incidence, presumably reflecting differences in the global distribution of risk factors, in addition to genetic variation. Risk factors for cholangio carcinoma have previously been reviewed elsewhere 1, 12 . Herein, we focus on the secular trends in the incidence of cholangiocarcinoma.
The incidence of iCCA and pCCA/dCCA
The international classification of cholangiocarcinoma does not, unfortunately, distinguish between pCCA and dCCA, and in this section we have aggregated these cancers together as 'pCCA/dCCA' . Together, pCCA (50-60%) and dCCA (20-30%) account for approxi mately 80% of all cholangiocarcinomas diagnosed in the USA; the remaining 20% are iCCA 13, 14 . The global incidence of cholangiocarcinoma is highest in northeast Thailand, with agestandardized incidence rates (ASIRs) of approximately 100 per 100,000 individuals among men and 50 per 100,000 individuals among women 15 ; in the West, ASIRs range between 0.5-2.0 per 100,000 indi viduals [15] [16] [17] . The high incidence of cholangiocarcinoma in Thailand and neighbouring areas has been attri buted to endemic liver fluke infection, in particular, with Opisthorchis viverrini 15 . Multiple studies reported that the incidence of iCCA increased by up to 10fold, while the incidence of pCCA/dCCA decreased at a sim ilar or slightly slower rate, over a 2-3decade period around the turn of the 20 th century in Australia, Japan, the USA, the UK, and across Europe 3, 4, [18] [19] [20] [21] . Given the poor prognosis of cholangiocarcinoma, patient mortality should parallel incidence rates. A study using data from the WHO revealed an overall decrease in agestandardized mortality rates (ASMR) among patients with pCCA/dCCA in the first decade of the 21 st century across 13 European Union (EU) countries (−6% in males, −17% in females), the USA (−20%, −17%), Japan (−5%, −10%), and Australia (−69%, −28%) 22 . By contrast, overall ASMRs for iCCA increased by 36.5% in males and 36.2% in females across the 13 EU countries, with the largest increases in Austria, Spain, France, Germany, Italy, and Denmark
22
. ASMRs for iCCA also rose in the USA (by 11.2% in men and 13.8% in women) and Australia (30.2%, 19.5%), but remained stable in Japan (0.4%, 0.3%) 22 . Two other stud ies, however, demonstrated that the incidence of both iCCA and pCCA/dCCA remained stable in Burgundy, 
Contributing factors
Several factors might explain the inconsistent trends in cholangiocarcinoma epidemiology, including some that are potentially artefactual. Cholangiocarcinoma classifi cation in large epidemiological datasets is problematic, owing to the lack of differentiation between pCCA and dCCA. Furthermore, International Classification of Disease for Oncology (ICDO; http://codes.iarc.fr/) edi tions change every few years, but are adopted by countries at different times. For example, the second edition of the ICDO (ICDO2) assigned 'Klatskin' tumours (pCCA) a unique histology code, but this was crossreferenced to the topography code for intrahepatic rather than extra hepatic cholangiocarcinoma. Using the ICDO3, however, Klatskin tumours can be cross referenced to either intra hepatic or extrahepatic cholangio carcinoma. In the USA, the switch from ICDO2 to ICDO3 occurred in 2001, whereas in the UK, this switch did not occur until 2008 (REF. 26 ). In a study of cholangiocarcinoma ASIRs between 1990 and 2008 in England and Wales 26 , a marked increase in iCCA and a decrease in pCCA/dCCA incidences were found, and remained evident after transferring all Klatskin tumours from intrahepatic to extra hepatic codes; however, only 1% of all cholangiocarcinomas were reportedly Klatskin, which cannot be a true reflection of all pCCA cases 26 . Of note, UK cancer registries reported that if a tumour site is unspecified, most would classify
Key points
• Each anatomical subtype of cholangiocarcinoma, intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA), has a distinct epidemiology, biology, and prognosis, thus necessitating different management approaches • Fluorescence in situ hybridization (FISH) has improved the diagnostic performance of conventional cytology for the detection of pCCA and dCCA; several emerging diagnostic modalities, including liquid biopsy techniques, might further improve cholangiocarcinoma diagnosis • Neoadjuvant chemoradiotherapy followed by liver transplantation offers the best outcomes for a subset of patients with pCCA; liver transplantation might also be an option for patients with very early stage iCCA • Emerging evidence indicates that high-dose, conformal external-beam radiation therapy is a potential treatment option for patients with localized, unresectable iCCA • An enhanced understanding of the potential driver genetic aberrations in cholangiocarcinomas has heralded several novel drugs for advanced-stage disease, including FGFR inhibitors and IDH inhibitors; targeted therapy and immunotherapy combinations also hold promise cholangiocarcinoma as intrahepatic 26 . In the same study 26 , an analysis of US Surveillance, Epidemiology, and End Results (SEER) data revealed that the ASIR of iCCA rose from 0.6 per 100,000 individuals in 1990 to 0.9 per 100,000 individuals in 2001; that year, concomitant with the uptake of ICDO3, the ASIRs for iCCA began to decrease, before plateauing at 0.6 per 100,000 individuals by 2007 (REF. 26 ). Conversely, ASIRs for pCCA/dCCA remained stable at around 0.8 per 100,000 individuals until 2001, and then began increasing, reaching 1.0 per 100,000 individuals by 2007 (REF. 26 ). These trends suggest that pCCA, the mostcommon subtype of cholangiocarcinoma, might have been misclassified as iCCA, the least common subtype, thereby falsely skewing the reported rates of iCCA.
Other studies have highlighted the misclassifi cation of cholangiocarcinoma. Systematic under reporting of the incidences of pancreatic cancer and cholangio carcinoma was found by examining the con cordance between Swedish cancer registries and patient registries: between 1990 and 2009, 44% of cholangio carcinomas were reported only in the patient registries 27 . In Sweden, most deaths from liver cancer are classified by the Cancer Register as 'unspecified' , and evidence indicates that the incidence of HCC is also under reported 28, 29 . The same classification and reporting issues probably apply to cholangiocarcinomas.
Whereas the incidence of iCCA has increased over the past 2-3 decades, a concomitant decline in the incidence of cancer of unknown primary (CUP) has been observed 2 . In a prospective, phase II trial involv ing patients with previously untreated CUP (n = 289) 30 , molecular tumour profiling enabled determination of the tissue of origin in 98% of patients. Of these, 18% of patients were predicted to have biliary tract cancer 30 . Hence, the enhanced clinical distinction between CUP and iCCA might be another factor contributing to the apparent increase in iCCA incidence 31 . Aside from technical classification issues, and improvements in the accuracy and availability of diag nostic tools, several demographic trends could also be affecting the true incidence of cholangiocarcinoma sub types, including rising obesity rates and the changing bur den of chronic viral hepatitis (which are recognized risk factors for iCCA, as well as for HCC 32 ); with improved antiviral therapy, the contribution of chronic viral hepa titis to the incidence of iCCA will probably decline in the future. Other demographic factors potentially influ encing the incidence of cholangiocarcinoma include population migration between different risk areas.
In conclusion, the trends in cholangiocarcinoma incidence are complex and need to be interpreted with caution. Going forward, epidemiological data need to be recorded uniformly and accurately; this responsibility resides with both clinicians and cancer registries.
Standard of care: diagnosis and therapy iCCA Diagnosis. iCCA is typically detected as a hepatic mass lesion, often during routine imaging surveillance for HCC in patients with cirrhosis; in a cirrhotic liver, the differential diagnosis of HCC and iCCA can be diffi cult. Whereas arterial phase enhancement with sub sequent delayed phase washout is diagnostic of HCCs 33 , dynamic gadoliniumenhanced MRI and CT scanning of iCCA yields an initial rim or peripheral arterial phase enhancement pattern followed by centripetal enhance ment in the delayed phases 34, 35 . CT and MRI have comparable performance in the detection of primary and satellite iCCA lesions, but CT imaging is superior for the detection of vascular enhancement and, thus, assessment of resectability 36 (FIG. 1) . Cancer antigen 19-9 (CA 19-9) is the primary serum biomarker used in the diagnosis of cholangiocarcinoma 37, 38 , and CA 19-9 levels >1,000 U/ml have been associated with the presence of meta static disease 39 . Of note, however, patients who are Lewisantigennegative (7% of the general population) have undetectable CA 19-9 levels 40 . A histo pathological assessment of a biopsy specimen is essential for the diagnosis of iCCA.
Surgical resection or liver transplantation. Surgical resection remains the mainstay of potentially curative therapy for iCCA (FIG. 2a) , with median diseasefree survival (DFS) durations of 12-36 months reported in various patient series 41, 42 . Notably, the median over all survival of patients with R0resected iCCA was 80 months in one cohort 13 . Predictors of short DFS durations include large tumour size, the presence of multiple liver lesions, and regional lymphnode involve ment 42 . Cirrhosis is also an independent factor associ ated with unfavourable survival outcomes in patients with iCCA undergoing surgical resection 43 . iCCA has conventionally been considered a contraindication for liver transplantation owing to poor survival outcomes and a high risk of recurrence 44, 45 . In 2014, however, a retrospective multicentre study demonstrated an excel lent 5year actuarial survival after liver transplantation of 73% in eight patients with cirrhosis and 'very early' iCCA, defined as single tumours ≤2 cm in diameter 46 . A followup study with a larger, international, multi centre cohort of patients found a 5year survival of 65% in 15 patients with very early iCCA versus 45% in 33 patients with 'advanced' iCCA (single tumour >2 cm or multifocal disease) 10 . These studies indicate that liver transplantation might be an effective treatment option for a subset of cirrhotic patients with early iCCA.
Locoregional therapies. Locoregional therapies are a reasonable treatment approach in patients with advancedstage iCCA (FIG. 2a) . In patients with localized, unresectable iCCA, transarterial chemo embolization (TACE) is considered a safe treatment option and is associated with median overall survival durations of 12-15 months [47] [48] [49] . In one such cohort, TACE with drugeluting beads resulted in a median overall survival of 11.7 months, compared with 5.7 months with con ventional TACE 50 . Radioembolization using yttrium90 microspheres is an alternate treatment option for unresectable iCCA, with reasonable effectiveness (median overall survival durations of 11-22 months) and safety 51, 52 (FIG. 2a) .
pCCA Diagnosis. A combination of CT and MRI with mag netic resonance cholangiopancreatography (MRCP) imaging is used for the detection of pCCA: MRI-MRCP has a higher level of diagnostic accuracy for the detec tion of biliary neoplastic invasion (FIG. 1) , whereas CT enables a better assessment of vascular involvement 53, 54 . The use of endoscopic ultrasonography (EUS) alone is associated with a high tumour detection rate compared with the use of CT or MRI, with better performance in the detection of dCCA versus pCCA (100% versus 83%, respectively) 55 . Fineneedle aspiration (FNA) during EUS carries a high risk of tumour seeding: among 191 patients with pCCA, 5 of 6 patients (83%) who under went a transperitoneal primary tumour biopsy devel oped peritoneal metastases, compared with 14 of 175 (8%) of those who did not undergo a transperitoneal biopsy 56 . Endoscopic retrograde cholangiopancreatog raphy (ERCP) has an integral role in pCCA management by enabling not only the detection of malignant biliary strictures, but also the acquisition of biliary brushing samples for cytological and genetic assessment.
A number of emerging cytological techniques have potential clinical utility in pCCA diagnosis
Conventional biliary cytology has a high specificity 57 , predominantly because cholangiocarcinomas are desmoplastic, paucicellular tumours potentially located in inaccessible regions of the biliary tree, caus ing difficulties in adequate specimen retrieval. FISH analyses have improved the diagnostic performance of conventional cytology. Chromosomal instability is a hall mark of cancer, and the diagnostic FISH assay involves the use of fluorescently labelled DNA probes to detect chromosomal aneusomy (gains or losses of chromo somal regions), with FISH polysomy indicating the pres ence of five or more cells with gains detected for two or more probes. An optimized FISH probe set targeting the 1q21, 7p12, 8q24, and 9p21 loci has been developed, and can detect pancreatobiliary malig nancies, including cholangiocarcinoma, with a sensitivity and specificity of 93% and 100%, respectively 7 . Nextgeneration sequenc ing (NGS) for known or candidate oncogenic targets can enhance the diagnostic utility of conventional bil iary cytology. In 33 patients with malignantappearing pancreatobiliary strictures, NGS combined with cytol ogy had a sensitivity of 85% in the detection of highrisk neoplasia or malignancy, compared with 67% for cytol ogy alone 58 . Moreover, NGS revealed driver mutations in 24 patients, including KRAS, TP53, and CDKN2A aberrations 58 . The cytological diagnosis of pCCA is not always possible, often necessitating a diagnosis based on clin ical criteria (for example, a mass lesion and malignant appearing stricture with elevated serum CA 19-9 levels); the major differential diagnosis for a perihilar stricture is pCCA versus IgG4 cholangiopathy 59 . Molecular profil ing techniques, however, have the potential to improve cholangio carcinoma diagnosis. For example, microRNAs (mi RNAs) have emerged as promising diagnostic mark ers
. Extracellular vesicles (EVs) are present in many biological fluids, including bile, and participate in intercellular communication; human biliary EVs con tain abundant miRNA species 60 . A panel of mi RNAs iso lated from EVs in bile had a reported sensitivity of 67% and a specificity of 96% for the diagnosis of cholangio carcinoma 60 . Furthermore, a separate proteomic ana lysis indicated that greater levels of oncogenic proteins are present in EVs obtained from cultures of human cholangio carcinoma cells versus those derived from non malignant human cholangiocytes 61 . In addition, Severino et al. 62 demonstrated that patients with malignant biliary strictures have a significantly higher concentration of EVs in bile than those with non malignant strictures (2.4 × 10 15 versus 1.6 × 10 14 nano particles/l in the discovery cohort, P <0.0001; 4.0 × 10 15 versus 1.3 × 10 14 nano particles/l in the verification cohort, P <0.0001). Moreover, these authors identified an EV proteomic signature that can help discriminate malignant from common nonmalignant bileduct strictures 62 . Genomic and molecular advances have increased the clinical utility of circulating tumour DNA (ctDNA) or cellfree DNA 63 . The plasma concentration of ctDNA correlates with tumour size and stage; hence, 'liq uid biopsy' approaches have the potential to be used for prognostication and disease monitoring in the 
. In 69 patients with cholangiocarcinoma (94% with pCCA) and 95 individ uals without cancer 64 , analyses of serum cellfree DNA revealed a panel of four genes that had differentially methylated regions (DMRs) in patients with cholangio carcinoma (HOXA1, PRKCB, CYP26C1, and PTGDR). This DMR ctDNA panel had a sensitivity and a speci ficity of 83% and 93%, respectively, in the detection of cholangiocarcinoma 64 .
Surgical resection or liver transplantation. Surgical resection of pCCA is a potentially curative option for patients without the following exclusion crite ria: bilateral involvement of the secondorder bile ducts, bilateral or contralateral vascular involvement, presence of metastatic disease, and underlying primary sclerosing cholangitis (PSC). PSC is associated with underlying chronic parenchymal disease and a field defect that can be eliminated by liver transplantation, but not resection. The presence of regional lympha denopathy, although not an absolute contraindication for resection, is associated with inferior patient outcomes 65 . Resection with curative intent often involves lobectomy with bileduct resection, regional lymphadenectomy, and RouxenY hepaticojejunostomy 65 . Surgical advances, such as extended lobectomy, vascular reconstruction, and techniques to increase remnant liver volume (including portal vein embolization and the associating liver par tition and portal vein ligation for staged hepatectomy (ALPPS) procedure), have facilitated the resection of tumours traditionally considered unresectable [66] [67] [68] [69] . Liver transplantation following neoadjuvant chemoradiation offers the best outcomes for patients with unresectable pCCA; however, only a minority of patients with early stage disease are candidates for this treatment option. Selection criteria -in an otherwise suitable candidate for liver transplantation -includes the presence of an unresectable tumour with a radial diameter of <3 cm, and the absence of intrahepatic or extrahepatic metastatic disease 70 . As alluded to previ ously, pCCA arising in the setting of PSC is best treated with liver transplantation regardless of resectability, owing to the field defect associated with this underlying chronic liver disease, which promotes carcinogenesis. Eligible patients typically undergo EBRT with radio sensitizing chemotherapy, brachytherapy, and main tenance oral chemotherapy before liver transplantation 9 . The 5year DFS of patients with pCCA who underwent liver transplantation following neoadjuvant therapy was 65% across 12 US transplantation centres 9 . For patients with pCCA who are not candidates for surgical resec tion or liver transplantation, consideration should be given to enrolment in a clinical trial, particularly those evaluating targeted therapy (FIG. 2b; Supplementary information S1 (table) ).
dCCA Diagnosis. The same modalities that are used for the diagnosis of pCCA -CT, MRI-MRCP, ERCP, and EUS -are used to diagnose dCCA (FIG. 1) . EUS with FNA of the lesion is usually diagnostic in patients with these tumours. The aforementioned molecular approaches to the diagnosis of pCCA might also be useful for the detection of dCCA.
Surgical resection. Surgical resection of dCCA typ ically entails a pancreaticoduodenectomy (Whipple procedure). In a large series of patients with cholangio carcinoma undergoing surgical resection 13 , R0 resection was achieved in 78% of those with dCCA. In this cohort, dCCAs were mainly resected using a Whipple procedure; for smaller tumours, excision of the extrahepatic biliary tree with lymphnode dissection was used 13 . The 5year overall survival of patients with dCCA was 23%, and was slightly higher (27%) if R0 resection was achieved (the median survival after R0 resection was 25 months) 13 . For patients with advancedstage dCCA not amenable to resection, consideration should be given to enrolment in a clinical trial, potentially involving targeted therapy (FIG. 2c; Supplementary information S1 (table)).
Cytotoxic chemotherapies
The combination of gemcitabine and cisplatin is the current firstline chemotherapy for patients with advancedstage cholangiocarcinoma not amenable to locoregional and surgical options, irrespective of ana tomical disease subtype. Valle et al. 11 reported a median survival of 11.7 months with this combination versus 8.1 months with gemcitabine alone; however, almost 40% of this cohort of patients in the UK had gallblad der cancer. Moreover, the 95% CI of the hazard ratio (HR) for death crossed one for the pCCA and dCCA subgroups 11 . A subsequent metaanalysis 71 , which incorporated data from the UK study 11 and a Japanese study 72 , among others, reported similar results for the gemcitabine and cisplatin regimen, with a median over all survival of 11.7 months -and 11.1 months in the UK and Japanese study cohorts specifically. These data indicate that, at least for patients with advancedstage pCCA/dCCA, enrolment in clinical trials of novel ther apies could be considered in lieu of treatment with the current standardofcare chemotherapy regimen (FIG. 2) .
Box 1 | Diagnosis of perihilar cholangiocarcinoma (pCCA)
Various emerging cytological and genetic techniques that can be performed on biliary brush specimens, bile, and serum for the detection of pCCA based on the presence and/or abundance of characteristic molecular markers are listed below. In the adjuvant setting, capecitabine has demon strated efficacy in patients who had undergone surgical resection for cholangiocarcinoma or gallbladder cancer: the median overall survival was 51 months in the treat ment arm compared with 36 months in the observation arm 73 . Results of a phase III trial conducted in France, however, demonstrated that adjuvant chemotherapy with gemcitabine and oxaliplatin (GEMOX), initiated 3 months after R0 or R1 resection of biliary tract cancer, did not significantly improve recurrencefree survival compared with placebo (HR 0.83, 95% CI 0.58-1.19; P = 0.31) 74 . More evidence is needed to clarify the role of adjuvant chemotherapy in the treatment of cholangiocarcinoma.
Cell-based assays on biliary brush specimens
The evolving role of radiation therapy Technological advances have improved the safety and effectiveness of radiation therapy for cholangio carcinoma 75 . Highresolution, multiphase helical CT and multiparametric MRI of the liver and biliary tree have enabled moreprecise determination of cancer loca tion and the extent of radiotherapy targeting. Moreover, CTbased treatment planning and dose calculation ena bles accurate estimation of radiation doses delivered to the tumour and nonmalignant tissues 76, 77 . In addi tion, advanced EBRT techniques, such as 3D confor mal radiotherapy (3D-CRT) and intensitymodulated radio therapy (IMRT), are used to deliver conformal radiation to the target while sparing nonmalignant tis sues. Alternatively, chargedparticle (proton or carbon) beams have a morefavourable physical dosedeposition profile than that of conventional Xray beams, which might yield advantages in sparing nonmalignant tissues 78 (FIG. 3) . Consequently, accelerated and hypo fractionated regimens, including stereotactic body radiation ther apy (SBRT), have been used to deliver highdose, abla tive EBRT to patients with cholangiocarcinoma [78] [79] [80] . Imageguided, highdoserate brachytherapy can also be used as primary treatment or to provide a radiation boost for selected patients with localized disease 81, 82 . Together, these technological advances might enable escalation of the radiotherapy dose to biliary tumours and/or improved protection of nonmalignant tissues, thus improving the therapeutic ratio for radiotherapy in the treatment of cholangiocarcinoma.
For patients with resected cholangiocarcinoma, data from retrospective studies indicate a benefit from post operative EBRT with concurrent chemo therapy, especially in patients with lymphnodepositive or resection marginpositive disease [83] [84] [85] . Results of a multi institutional, singlearm phase II study 86 demonstrated the safety and promising efficacy of adjuvant therapy consisting of gemcitabine plus capecitabine followed by conformal EBRT with concurrent capecitabine for patients with resected pCCA/dCCA and gallbladder can cer. The majority of patients (81%) received IMRT 86 . In the 54 patients with resected pCCA/dCCA, the 2year overall survival and local control rates were 68% and 87%, respectively; no differences in overall survival or DFS were observed between patients with R0 versus R1 resection 86 . These results support the need for high quality studies of adjuvant chemo radiotherapy for patients with resected cholangiocarcinoma.
Studies have demonstrated the safety and efficacy of highdose, conformal EBRT for patients with localized, unresectable iCCA 78, 80 . In a singleinstitution retro spective analysis 80 involving 79 patients with localized, unresectable iCCA treated with highdose, conformal EBRT (35-100 Gy, median 58.05 Gy, in 3-30 fractions), the median overall survival was 30 months. In a multi institutional singlearm phase II study 78 , 37 patients with localized, unresectable iCCA received hypofractionated protonbeam therapy with a median dose of 58.05 Gy in 15 fractions delivered daily over 3 weeks. The median and 2year overall survival was 22.5 months and 46.5%, respectively; the 2year local control rate was 94%, and most recurrences occurred at extrahepatic sites 78 . These outcomes formed the basis for an ongoing multi institutional phase III trial to assess the role of highdose, conformal EBRT after initial gemcitabine and cisplatin chemotherapy (NCT02200042).
For patients with localized, unresectable pCCA/ dCCA, the role of radiotherapy remains unclear. Retrospective analyses of large observational cohorts suggest a modest benefit from radiotherapy, although these analyses are hampered by considerable inherent biases 87, 88 . By contrast, in singleinstitution retro spective series [89] [90] [91] , longterm DFS has been reported for a small subset of patients treated with definitive chemo radiotherapy. Randomized trials are needed to better define the relative roles of contemporary treatments for localized, unresectable pCCA/dCCA, including systemic therapies and modern locoregional radiotherapy (FIG. 2) . Proton-beam radiotherapy plan for a patient with localized, unresectable iCCA, with a total radiation dose of 6,750 cGy delivered in 15 fractions over 3 weeks. The orange line depicts the tumour. The white, cyan, magenta, and yellow lines represent the 6,750, 5,000, 3,000, and 1,000 cGy isodose lines, respectively. Radiation is delivered in two beams from the right lateral (R) and posterior (P) directions (as indicated by the 1,000 cGy isodose lines). Proton beams have no 'exit dose' deposition, which for this patient, enabled complete sparing of the left lobe of the liver, stomach, and bowel from radiation exposure. 
Molecular pathogenesis
The marked intertumoural and intratumoural hetero geneity of cholangiocarcinoma has contributed to the lack of effective targeted therapies for this deadly dis ease. Moreover, in most clinical trials, investigators have grouped together patients with different subtypes of the disease, under the broad definition of 'biliary tract cancer' , rather than stratifying patients according to the presence of relevant oncogenic drivers. Molecular pro filing studies have better delineated the genomic and transcriptomic landscape of each cholangiocarcinoma subtype (FIG. 4) . Comprehensive wholeexome and tran scriptome sequencing in a large cohort of 260 patients with biliary tract cancers, including 145 with iCCA, 86 with pCCA/dCCA, and 29 with gallbladder cancer, revealed potentially targetable genetic driver alterations in ~40% of patients 92 . In this study by Nakamura et al. 92 , the repertoire of genetic alterations varied across the different cholangiocarcinoma subtypes. For example, recurrent mutations in IDH1, IDH2, FGFR1, FGFR2, FGFR3, EPHA2, and BAP1 were noted predominantly in iCCAs, whereas ARID1B, ELF3, PBRM1, PRKACA, and PRKACB mutations occurred preferentially in pCCA/dCCA 92 . The characteristic genomic signatures associated with the different genetic aberrations in each disease subtype contribute to their distinct biological behaviour. Notably, fibroblast growth factor receptor 2 (FGFR2) fusions that result in ligandindependent acti vation of this receptortyrosine kinase were identified exclusively in patients with iCCA 92 , consistent with prior observations [93] [94] [95] [96] [97] . Novel gene fusions involving PRKACA or PRKACB, which encode catalytic sub units of protein kinase A, were detected only in pCCA/dCCA 92 . The discovery of these aberrations is important because gene fusions are often targetable driver events. ELF3 was another novel candidate driver gene identified in this study 92 , primarily in pCCA/dCCA. Inactivating mutations in ELF3 have since been identified in dCCA samples in two other genomic analyses 98, 99 ; thus, the ETSrelated transcription factor ELF3 probably acts as a tumour suppressor in cholangiocarcinoma. In keep ing with data reported by Nakamura et al. 92 , targeted sequencing of selected cancerrelated genes in a study of 28 iCCA samples revealed potentially actionable alterations in IDH1, IDH2, FGFR2, KRAS, PTEN, and CDKN2A, among others 95 . The most common alter ations involved ARID1A, IDH1, IDH2, and TP53 (each identified in 36% of the tumours), as well as MCL1 (amplified in 21% of tumours) 95 . Discrete carcinogenic exposures might induce dis tinct somatic alterations in patients with cholangio carcinomas, as highlighted by wholeexome sequencing data from 108 liverflukerelated and 101 nonliver flukerelated tumours 100 : nonliverflukerelated iCCAs had a higher prevalence of mutations in IDH1 or IDH2 (encoding isocitrate dehydrogenase [NADP] cytoplasmic (IDH1) and mitochondrial (IDH2)), and lossoffunction mutations in the tumour suppressor gene BAP1 (encoding the epigenetic regulator BRCA1associated protein 1 (BAP1)) 100 . By contrast, mutations in the tumoursuppressor gene TP53 were a more frequent occurrence in liverflukerelated cholangio carcinomas 100 . These findings suggest that distinct causative aetiologies determine the mutational landscape of cholangiocarcinoma.
An integrated genomic analysis of predominantly liverflukenegative, hepatitisnegative iCCAs by The Cancer Genome Atlas (TCGA) investigators 101 iden tified inactivating mutations in tumoursuppressor genes, including ARID1A, ARID1B, BAP1, TP53, and PTEN, and gainoffunction mutations in the onco genes IDH1, IDH2, BRAF, and KRAS -recapitulating the afore mentioned findings. Recurrent focal losses of CDKN2A, encoding p16
INK4A
, which inhibits the cyclin dependent kinases CDK4 and CDK6 (as well as p14 ARF , which also indirectly inhibits CDK4 and CDK6), were observed in 47% of the tumours 101 -a substantially higher pro portion than reported previously (7-15%) 95, 102 . Consistent with prior reports 92, 95, 103, 104 , mutations in IDH1 or IDH2 were detected exclusively in iCCA, and were highly enriched in a novel, distinct molecular iCCA subtype identified through clusterofcluster analysis of gene expression, DNAmethylation, and copynumber profiles 101 . Interestingly, this subtype was associated with high and low levels of mitochondrial and chromatin modifier gene expression, respectively, including prob able epigenetic silencing of ARID1A 101 , which encodes , is currently being investigated in a phase II study in patients with advancedstage cholangiocarcinoma harbouring FGFR alterations (NCT02150967). An interim analysis of data from this study indicated that NVPBGJ398 has impres sive antitumour activity, with a diseasecontrol rate of 82%, and a manageable safety profile 106 . Erdafitinib is another orally active, panFGFR inhibitor 107 , and is being investigated in clinical trials. In a phase I doseescalation study (NCT01703481), erdafitinib had a manageable safety profile at doses associated with clinical responses; among 23 responseevaluable patients with solid tumours harbouring FGFRpathway alterations, four patients had a confirmed response to treatment with erdafitinib, one had an unconfirmed partial response, and 16 had sta ble disease 108 . A phase II trial of erdafitinib is currently ongoing (NCT02699606). Other FGFRselective inhibi tors currently being evaluated in patients with advanced stage solidorgan malignancies include derazantinib (NCT01752920), TAS120 (NCT02052778), Debio 1347 (NCT01948297), and INCB054828 (NCT02924376, NCT02393248). Ponatinib, a nonselective tyrosine kinase inhibitor, has shown promising efficacy in patients with advancedstage iCCA with FGFR2 fusions 93 , and is currently being evaluated in a phase II trial in this pop ulation (NCT02265341; Supplementary information S1 (table)).
Inhibition of heatshock protein 90 (HSP90) is an alternative to direct FGFRkinase inhibition in FGFR2fusiondriven cancers. HSP90 is a molecular chaperone required for essential cellular house keeping functions, such as protein folding and mediating posttranslational protein homeostasis, as well as for maintenance of oncoprotein stability 109 . As proof of this concept, the selective HSP90 inhibitor ganetespib induced loss of fusion protein expression, inhibition of oncogenic signalling, and consequent cancercell cytotoxicity in FGFRfusiondriven bladder cancer 110 . Moreover, ganetespib had a synergistic combi natorial benefit with NVPBGJ398 in preclinical models, with a change in average tumour volume relative to the vehicletreated animals of −23% for ganetespib alone, −20% for NVPBGJ398 alone, and −66% for the combination 110 . ROS1 kinase fusion proteins have an oncogenic role in several malignancies, including cholangiocarcinoma; an immunoaffinity profiling study revealed FIG-ROS1 gene fusions in 2 of 23 patients with cholangio carcinoma (8.7%) 111 . In a mouse orthotopic allograft model, expres sion of the FIG-ROS1 fusion accelerated iCCA tumour development and inactivation of this fusion had the converse effect, indicating that ROS1 fusions are potent oncoproteins and a potential therapeutic target in cholangio carcinoma 112 . Of note, a gene fusion involving the ROS1related kinase ALK (EML4-ALK) has also been detected in a patient with iCCA 92 . The ALK and ROS1 inhibitor ceritinib is currently being evaluated in two phase II trials in patients with ROS1positive or ALKpositive advancedstage pCCA or iCCA (NCT02374489; Supplementary information S1 (table)), or advancedstage gastrointestinal malignancies, includ ing cholangiocarcinoma (NCT02638909). Entrectinib, a selective tyrosinekinase inhibitor with activity against ROS1 and ALK (as well as TRKA, TRKB, and TRKC), is also being evaluated in a phase II study involving patients with advancedstage solid tumours harbouring ROS1 or ALK fusions (NCT02568267).
Activating mutations of the protooncogene KRAS are a frequent occurrence (11-25%, depending on dis ease subtype) in cholangiocarcinomas 92, 95, 101 , and are associated with unfavourable progressionfree sur vival (PFS) and overall survival 95, 102, 113 . KRAS activation up regulates signalling via downstream pathways, includ ing the RAF-MEK-ERK (MAPK) pathway. Accordingly, KRASmutant cholangiocarcinomas might be amenable to MEK inhibition. Results of a phase II study of selu metinib in patients with metastatic biliary cancer demon strated a median PFS of 3.7 months and a median overall survival of 9.8 months 114 . In a subsequent phase Ib study in patients with advancedstage biliary tract cancer, the combination of selumetinib, gemcitabine, and cisplatin conferred a median PFS of 6.4 months 115 . Neither of these studies involved patient selection based on KRAS mutation status. BRAF mutations can also occur in cholangiocarcinoma (predominantly in iCCAs), albeit at a low frequency (3-5%) 102, 113, 116 . In eight patients with BRAF V600mutated cholangiocarcinoma, treatment with the oral BRAF inhibitor vemurafenib led to a partial response in one patient 117 . Tyrosinekinase signalling via the hepatocyte growth factor receptor MET is essential to a myriad of cellular processes required for cell survival. An integrated molec ular analysis identified a proliferation class of iCCAs (62% of all iCCAs) characterized by activation of MET, EGFR, and MAPK signalling 118 ; however, the results of early phase clinical trials of MET or EGFR inhibitors in patients with cholangiocarcinoma have been disappoint ing. A phase I study 119 of the MET inhibitor tivantinib in combination with gemcitabine in patients with solid tumours, including cholangiocarcinoma, demonstrated partial responses and stable disease in 20% and 46% of patients, respectively; one patient with cholangio carcinoma had a partial response. Cabozantinib, a multikinase inhibitor with activity against MET and VEGFR2, had limited activity (median PFS 1.8 months) and substantial toxicity in unselected patients with cholangio carcinoma 120 . Moreover, MET expression did not correlate with patient outcomes in this study 120 .
The combination of sorafenib, a multikinase inhibitor with activity against VEGFR and RAF family kinases, and the EGFR inhibitor erlotinib had disappointing clinical activity against advancedstage biliary tract cancer 121 . In fact, this phase II study 121 was terminated early owing to suboptimal PFS and overall survival. A phase II trial of the antiHER2 antibody-drug con jugate trastuzumab emtansine (TDM1) in patients with HER2positive advancedstage malignancies, including cholangiocarcinoma, is currently ongoing (NCT02999672; Supplementary information S1 (table)). Umbrella and basket trial designs could facilitate the testing of these agents in what are essentially very rare molecular subtypes of cholangiocarcinoma.
Therapeutics targeting epigenetic alterations. The afore mentioned genetic profiling studies have revealed that mutations affecting epigenetic regulators, such as IDH1, IDH2, BAP1, and ARID1A, are common in cholangio carcinomas 92, 95, 100, 101 ; thus, epigenetic therapies are a promising endeavour 122 . Smallmolecule inhibitors of mutant IDH1 or IDH2 have shown favourable efficacy in preclinical studies 123, 124 ; consequently, orally bio available inhibitors have entered clinical trials. Preliminary results from a phase I trial of AG120 (NCT02073994; Supplementary information S1 (table)), an inhibitor of mutant IDH1, in a doseescalation and doseexpansion cohort of patients with cholangiocarcinoma harbour ing IDH1 mutations indicated a favourable safety pro file 125 . Moreover, among 20 responseevaluable patients with cholangiocarcinoma treated with AG120 in this study 125 , one had a partial response and 11 had stable disease. ClarIDHy, a global, multicentre, doubleblind, placebocontrolled phase III trial involving 186 patients with IDH1mutant cholangiocarcinoma, is currently underway (NCT02989857). Enasidenib, a firstinclass, oral, selective inhibitor of mutant IDH2, has demon strated activity in preclinical models of acute myeloid leukaemia (AML) [126] [127] [128] . Consequently, enasidenib has been granted priority review by the FDA for patients with AML harbouring an IDH2 mutation. Enasidenib is currently being investigated in a multicentre phase I/II trial in patients with IDH2mutant advancedstage solid tumours, including iCCA (NCT02273739; Supplementary information S1 (table) ).
Of note, IDHmutant iCCA cells are dependent on SRC activity for survival; the SRC kinase inhibitor dasat inib induced tumour regression of mouse IDHmutant tumour xenografts 129 . This preclinical work provided the basis for a phase II trial of dasatinib in patients with advancedstage IDHmutant iCCA (NCT02428855; Supplementary information S1 (table) ). In addition, the TCGA analysis suggests that IDHmutant chol angiocarcinomas probably have epigenetic silencing of the SWI/SNF chromatinremodelling complex protein ARID1A 101 . In fact, mutation or silencing of SWI/SNF chromatin remodelling subunits, including ARID1A, ARID1B, ARID2, BAP1, PBRM1, SMARCA2, SMARCA4, and SMARCAD1, is a frequent occurrence in cholangiocarcinomas (and other cancers) 92, 101, 130 . Notably, tumours with mutations in genes encoding members of the SWI/SNF complex are dependent on the histone methyltransferase activity of EZH2 and, hence, are potentially susceptible to EZH2 inhibitors 130 . Indeed, EZH2 is typically overexpressed in cholangio carcinomas, and EZH2 upregulation is correlated with a poor prognosis 131, 132 . Furthermore, preclinical data indi cate that EZH2 inhibition, in combination with gemcit abine, synergistically inhibits cholangiocarcinoma cell proliferation 133 . Several active clinical trials are investigating EZH2 inhibitors, such as tazemetostat, but primarily in patients with haematopoietic or rhab doid tumours. Trials of such agents in patients with cholangiocarcinoma are warranted.
The recurrent, inactivating mutations in chromatin regulators, including BAP1, ARID1A, ARID1B, ARID2, PBRM1, SMARCA2, SMARCA4, and SMARCAD1, support the notion that cholangiocarcinoma has an epigeneticallyinclined mutational spectrum 92, 122, 134, 135 . Loss of expression of ARID1A and PBRM1 seems to be a late event in cholangiocarcinoma carcinogenesis 136, 137 . Several smallmolecule inhibitors targeting chroma tinremodelling proteins are under investigation in preclinical and clinical studies of cholangiocarcinoma. These agents include histone deacetylase (HDAC) inhib itors, such as vorinostat, romidepsin, and valproic acid, and DNA methyltransferase (DNMT) inhibitors, includ ing azacitidine and decitabine [138] [139] [140] [141] [142] . Results of a phase I/II study of valproic acid in 12 patients with advancedstage pancreaticobiliary tract cancers indicate promising antitumour activity, with one patient achieving a par tial response, 10 having stable disease, and one having progressive disease 143 .
Novel potential targeted therapies. Mesothelin, a cellsurface protein expressed in nonmalignant meso thelial cells, is often aberrantly expressed in cholangio carcinomas, and is associated with advancedstage and metastatic disease, and unfavourable overall sur vival 144, 145 . Thus, this protein is an attractive target for therapy. Anetumab ravtansine, an antimesothelin antibody-drug conjugate, is being tested in a phase I trial open for enrolment of patients with advancedstage cholangiocarcinoma with aberrant mesothelin expres sion (NCT03102320; Supplementary information S1 (table)).
The recurrent focal losses of CDKN2A, a gene encod ing the proteins p16 INK4A and p14 ARF that are essential neg ative regulators of cellcycle progression 92, 95, 101 , highlight the potential of CDK4/6 inhibitors, such as ribociclib and palbociclib, in the treatment of cholangiocarcinoma. These agents are approved treatments for breast cancer, and are in clinical trials for a range of other solidorgan malignancies (NCT03065062, NCT02022982), although the efficacy of these agents remains to be evaluated in patients with cholangiocarcinoma.
Somatic mutations of the tumoursuppressor genes BRCA1 and BRCA2 have been reported in cholangio carcinomas 92, 102 . BRCAmutated tumours are often sensitive to poly [ADPribose] polymerase (PARP) inhi bition. Accordingly, in a retrospective clinical analysis in patients with BRCAmutated cholangiocarcinoma (n = 18), one of the four patients who received PARP inhibitors had a sustained disease response with a PFS duration of 42.6 months 146 . Although PARP inhibitors and inhibitors of ataxiatelangiectasia mutated (ATM), another DNArepair protein, are currently being evalu ated in multiple clinical trials for BRCAmutated breast cancer, they have yet to be prospectively evaluated in patients with cholangiocarcinoma. A phase II trial of the PARP inhibitor niraparib is, however, planned in patients with advancedstage malignancies, includ ing cholangiocarcinoma, and with known mutations in BAP1 and other DNA doublestrand break repair pathway genes -excluding, for an unspecified reason, BRCA1/2 mutations (NCT03207347; Supplementary information S1 (table)).
Immunotherapy for cholangiocarcinoma
Immunotherapy in oncology. The immune system holds the remarkable potential to recognize and destroy aberrant cancer cells, but is regulated by a complex network of immune checkpoints that pre vent uncontrolled immune activation. Cancers har ness several mechanisms of immune escape to restrain or evade antitumour immune responses, including modulation of the local tumour microenvironment to create an immunosuppressive milieu; expression of immunecheckpoint proteins, such as cytotoxic Tlymphocyteassociated antigen 4 (CTLA4) and programmed cell death protein 1 (PD1); and loss of MHC expression. The exact mechanisms underlying the immune escape of cholangiocarcinomas remain to be elucidated. Immunecheckpoint inhibitors, anti bodies that block the inhibitory interactions between CTLA4 or PD1 and their cognate ligands (FIG. 5) , have demonstrated robust and durable antitumour activity in subsets of patients across a variety of tumour types, coupled with low rates of immunemediated toxic ity 147 . Indeed, various immunecheckpoint inhibitors have now been approved for use in the treatment of several malignancies. Ongoing studies of these agents, combination therapies, and novel adoptivecell ther apies 148 show great promise to identify novel indi cations, improve upon the current response rates, refine treatment selection and sequencing, and address therapy resistance.
Rationale for and risks of immunotherapy in cholangiocarcinoma. In cholangiocarcinoma, a number of clinical and epidemiological factors might determine both the efficacy, and the potential risks associated with immunotherapy. A number of chronic infections, such as liverfluke disease, viral hepatitis B and C, and bac terial pyogenic cholangitis, are established risk factors for chol angiocarcinoma 1, 149 . Notably, immune checkpoint inhib itors and other immunotherapies have shown promising efficacy in other tumours commonly associated with viral infections, such as head and neck cancer, Hodgkin lymphoma, Merkelcell carcinoma, and HCC
150
, and this relationship is thought to be mediated, in part, by the presentation of nonself or neoantigens associated with viral infections [150] [151] [152] . Notably, tran scriptome sequencing and clustering of geneexpression profiles revealed a subgroup of patients with cholangio carcinomas with a high mutational load, resulting in abundant tumour specific neoantigens, and enrichment for expression of immunerelated genes, including genes encoding inhib itory immunecheckpoint proteins 92 . Interestingly, this patient subgroup had the poorest prognosis 92 . These findings support the hypothesis that some patients with cholangiocarcinoma might benefit from immunecheck point inhibition to 'release the brake' on an existing anticancer immune response.
Indeed, a substantial proportion of cholangio carcinomas are surrounded by a reactive tumour stroma, populated by host cells including cancer associated fibroblasts, endothelial cells, and immune cells, including tumourassociated macrophages (TAMs) 153, 154 . These stromal elements produce soluble factors including various interleukins, growth factors, and cytokines, which in turn can promote tumourcell proliferation, survival, and invasiveness, and modulate anticancer immune responses. In a small retrospective study involving 39 patients with cholangiocarcinoma, high numbers of alternatively activated, 'M2like' TAMs, which are generally considered to be immuno suppressive, were associated with unfavour able disease free survival 155 . Thus, targeting stromal cells, such as immuno suppressive TAMs or cancerassociated fibroblasts [156] [157] [158] , might prove to be a beneficial thera peutic strategy, particularly in combination with immuno therapy (FIG. 5; TABLE 1 ).
Prevalent hepatic dysfunction and the propensity for biliary obstruction in patients with cholangio carcinoma is associated with high rates of adverse events in studies of cytotoxic therapies 11 , and raises con cerns regarding an increased risk of immune mediated hepatobiliary toxicity, such as cholestasis or hepatitis, with immunecheckpoint inhibition. Reassuringly, in the phase I/II CheckMate 040 trial 159 , the incidence of grade 3 or 4 immunemediated transaminase elevation among 214 patients with HCC who received the PD1 inhibitor nivolumab was approximately 4% (similar to the rates reported for patients with other tumour types), without any reported treatmentrelated hepatic decompensation. Autoimmune diseases, such as PSC and inflammatory bowel disease, are also known risk factors in a subset of patients with cholangiocarcinoma, raising additional concerns regarding the risk of flares in preexisting colitis or biliary tract disease with the use of immune activating therapies in this population. Of note, patients with underlying autoimmune disease have typically been excluded from clinical trials of immuno therapies; thus, the safety of such treatments in this subset of patients with cholangiocarcinoma remains uncertain.
Candidate biomarkers of response to immunotherapy. Many candidate biomarkers of a response to immunecheckpoint inhibition have emerged from studies relating to a range of tumour types. The most studied biomarker to date is the PD1 ligand, PDL1; any expression of PDL1 on tumour cells, and/or higher levels of tumour PDL1 expression have both been asso ciated with sensitivity to immunecheckpoint inhibitor mono therapy in some tumour types, including mela noma and nonsmallcell lung cancer (NSCLC), but with conflicting results in other diseases [160] [161] [162] . In studies of small numbers of cholangiocarcinoma tumour sam ples (n = 54-99), PDL1 expression has been reported in 9-72% of specimens [163] [164] [165] , and on 46-63% of immune cells within the tumour micro environment 164, 165 . These data indicate that a substantial proportion of cholangio carcinomas might be amenable to therapy with PD1 or PDL1 inhibitors. Further investigation of PDL1 as a biomarker for antiPD1 and antiPDL1 therapies is required in order to understand the effects of important covariates, including tumourcell versus immunecell expression, primary versus metastatic lesion sampling, prior treatment exposure, and concurrent therapies, as well as the specific assay and cutoff points used.
Certain tumour genetic aberrations have also been associated with a likelihood of response to immunecheckpoint inhibitors, which might relate to the expression of neoantigens capable of eliciting an antitumour Tcell response. One example is the presence of tumour DNA mismatch repair (MMR) In combination with immune-checkpoint inhibition, intravenous adoptive transfer of tumour-infiltrating lymphocytes (TILs) isolated from the TME and expanded ex vivo might enhance anticancer immunity. Alternatively, targeting the vascular endothelial growth factor receptor 2 (VEGFR2) with the monoclonal antibody ramucirumab might enhance T-cell recruitment into the TME, as a result of normalization of the dysfunctional tumour vasculature, and can also have direct, beneficial immunological effects, for example, on tumour-associated macrophages. Immune-checkpoint inhibitors are also being combined with helper cytokines that might potentiate anticancer immunity, such as granulocyte-macrophage colony-stimulating factor (GM-CSF) and pegylated IFNα-2b (Peg-IFNα-2b), as well as small-molecular inhibitors of targets relevant to cholangiocarcinoma, such as fibroblast growth factor receptors (FGFR1-3) and heat-shock protein 90 (HSP90). ACT, adoptive cell therapy; MHC I, major histocompatibility complex class I; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolization; TCR, T-cell receptor; T reg cell, regulatory T cell. A www.ClinicalTrials.gov search was performed using the terms "biliary tract", "bile duct", "biliary cancer", and "cholangiocarcinoma" (last updated 19 June 2017), and identified immunotherapy trials with a status of "Not yet recruiting", "Recruiting", "Enrolling by invitation", and "Active, not recruiting" were included; trials without inclusion of a specific biliary cancer cohort or without adequate information available were excluded. CCA, cholangiocarcinoma; CTLA-4, cytotoxic T-lymphocyte-associated antigen 4; FGFR1-3, fibroblast growth factor receptors 1-3; GM-CSF, granulocyte-macrophage colony-stimulating factor; HSP90, heat-shock protein 90; PD-1, programmed cell death protein 1; PD-L1, programmed cell death 1 ligand 1; Peg-IFNα-2b, pegylated IFNα-2b; RFA, radiofrequency ablation; SBRT, stereotactic body radiation therapy; TACE, transarterial chemoembolization; VEGFR2, vascular endothelial growth factor receptor 2.
deficiency and/or microsatellite instability (MSI), which is associated with high rates and durability of responses to immunecheckpoint blockade across multiple tumour types 166, 167 . Indeed, the antiPD1 antibody pembrolizumab has been approved by the FDA for the treatment of patients with unresectable or metastatic MMRdeficient and/or MSIhigh solid tumours that progressed after prior therapy (when no satisfactory alternative treatment is available), inde pendent of histology -which would include those with cholangio carcinoma (https://www.fda.gov/drugs/ informationondrugs/approveddrugs/ucm279174. htm). Notably, MMR deficiency has been reported to occur in 5-10% of cholangiocarcinomas 168 . In addi tion to MMR deficiency, the cumulative tumour mutational burden has been correlated with respon siveness to immunecheckpoint inhibitors in some cancers, including melanoma, NSCLC, and uro thelial carcinoma [169] [170] [171] . In a wholeexomesequencing study of 231 cholangiocarcinoma tumour samples 92 , a median of 39 and 35 somatic nonsynonymous muta tions were identified in intrahepatic and extrahepatic cholangiocarcinomas, respectively; overall, ~6% of the cholangiocarcinomas had evidence of hypermutation (mutation rates of >11.13 per megabase; median num ber of 641 nonsilent mutations), with concurrent MMR deficiency and/or MSI detected in about 36% of these hypermutated tumours 92 . For comparison, in patients with NSCLC who derived durable clinical benefit from pembrolizumab (partial or stable response lasting >6 months), the median number of nonsynonymous mutations was 302 (REF. 169 ). These data suggest that immunecheckpoint blockade and immunemodulating therapies could be promising options for the subgroup of patients with cholangiocarcinomas harbouring high mutational loads.
Emerging clinical data from immune-targeted therapies in cholangiocarcinoma. At present, the clinical data on immunotherapy in cholangiocarcinoma and other biliary tract cancers are limited. Interim safety and efficacy data from the KEYNOTE028 basket trial (NCT02054806) of the antiPD1 antibody pembroli zumab have been reported for a small cohort of patients with PDL1positive biliary tract cancer 163 ; 37 of 89 patients screened (41.6%) had PDL1 expression on ≥1% of tumour cells by immunohistochemistry, 24 of whom enrolled in the study (20 with cholangio carcinoma, four with gallbladder carcinoma) 163 . Of these 24 patients, four (17%, three with cholangiocarcinoma and one with gallbladder carcinoma) had a partial response, and four (17%) had stable disease 163 . The duration of partial response was protracted, with the median PFS not reached at the time of reporting. The rate of grade 3 toxicities was 16.7%, with no patients experiencing grade ≥4 toxicities, nor any marked hepatotoxicity 163 . The promising safety and efficacy of pembrolizumab in the KEYNOTE028 biliary cancer cohort prompted a successor biliary cancer cohort of 100 patients in the ongoing KEYNOTE158 basket trial (NCT02628067; Patients with MMRdeficient cholangiocarcinoma have also demonstrated responsiveness to treatment with immunecheckpoint inhibitors 166, 167, 172 . Among 86 patients with MMRdeficient tumours, encompass ing 12 different tumour types including cholangio carcinoma (n = 4), PD1 blockade with pembrolizumab resulted in objective radiographic responses in 53% of patients, and in 25% of patients with cholangio carcinoma (one of the patients with cholangio carcinoma had a complete response, and the other three had stable disease, for a diseasecontrol rate of 100%) 172 ; median PFS and overall survival were not reached at the time of publication 172 . These provocative preliminary clinical data hold promise for immunotherapy approaches in cholangiocarcinoma, while underscoring the impor tance of biomarker development to identify patients who are most likely to respond, and to guide the rational selection of combination therapies. A number of clinical trials evaluating novel immunotherapy approaches in patients with cholangiocarcinoma are currently ongoing (TABLE 1) .
Conclusions
Cholangiocarcinomas are anatomically distinct and genetically heterogeneous tumours. Current modali ties for establishing a cholangiocarcinoma diagnosis are insufficient, as detection of the disease at a sufficiently early stage to enable potentially curative surgical ther apies remains an arduous task. Novel biomarkers that merit further investigation include DNAmethylation markers, noncoding RNAs, and peptide panels 60, [173] [174] [175] . Thus, one can envision the application of advanced technologies such as proteomic analysis by mass spec trometry or 2D gel electrophoresis, and microRNA analysis for the detection of cholangiocarcinoma bio markers in biological specimens, including bile, serum, or stool samples. In addition, FISH could potentially be used to detect novel gene fusions in patients with cholangiocarcinoma.
An enhanced understanding of the driver genetic aberrations in each disease subtype is integral to estab lishing a precision medicine approach to cholangio carcinoma therapy. Moreover, recently described gene fusions and mutations in cholangiocarcinoma need further investigation in functional studies and clinical trials. Emerging therapies that hold considerable prom ise include FGFR inhibitors and IDH1 and/or IDH2 inhibitors, as well as immunotherapies. Identification of biomarkers for the selection of patients harbouring perti nent genetic aberrations is an essential factor in targeted therapy. In future trials, patients should be stratified according to disease subtype and genetic drivers. Such biomarkerdriven trials will be imperative in the devel opment of effective medical therapies for cholangio carcinoma. The extensive interactions and crosstalk between the various signalling pathways involved in cholangiocarcinoma carcinogenesis highlights the importance of combination therapeutic approaches. In particular, the combination of molecularly targeted agents and immunotherapy with immunecheckpoint inhibitors merits further investigation.
